Literature DB >> 12051754

CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.

Katsunori Nakamura1, Noritaka Ariyoshi, Tsuyoshi Yokoi, Satoru Ohgiya, Michihiro Chida, Kazuo Nagashima, Kazuaki Inoue, Takao Kodama, Noriaki Shimada, Tetsuya Kamataki.   

Abstract

Comparing bufuralol 1'-hydroxylase activity among liver microsomes prepared from individuals whose CYP2D6 genotypes had been determined, we found that the activity tended to decrease depending on the number of the CYP2D6*10 allele. Pre-incubation of liver microsomes from individuals homozygous for the CYP2D6*10 allele resulted in a decrease in the enzyme activity more rapidly than those from individuals homozygous for the CYP2D6*1, suggesting that not only the catalytic activity but also the thermal stability of the enzyme appeared to be affected by the genetic polymorphism. To confirm this hypothesis, the kinetic parameters of CYP2D6.1 and CYP2D6.10 were compared for bufuralol 1'-hydroxylation and dextromethorphan O-demethylation using microsomes prepared from yeast transformed with plasmids carrying CYP2D6 cDNAs (*1A and *10B). Kinetic studies of these CYP2D6 forms indicated clear differences in the metabolic activities between the wild (CYP2D6.1) and the mutant enzymes (CYP2D6.10). Bufuralol 1(')-hydroxylase activity in microsomes of yeast expressing CYP2D6.10 was rapidly decreased by heat treatment, supporting the idea that the thermal stability of the enzyme was reduced by amino acid replacement from Pro (CYP2D6.1) to Ser (CYP2D6.10). These data strongly suggest that the thermal instability together with the reduced intrinsic clearance of CYP2D6.10 is one of the causes responsible for the known fact that Orientals show lower metabolic activities than Caucasians for drugs metabolized mainly by CYP2D6, because of a high frequency of CYP2D6*10 in Orientals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12051754     DOI: 10.1016/S0006-291X(02)00328-5

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.

Authors:  Marisol López; Jorge Guerrero; Helgi Jung-Cook; María Elisa Alonso
Journal:  Eur J Clin Pharmacol       Date:  2005-10-26       Impact factor: 2.953

2.  Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters.

Authors:  Vera Kim; Thijs van der Wal; Miriam Yumie Nishi; Luciana Ribeiro Montenegro; Flair Jose Carrilho; Yujin Hoshida; Suzane Kioko Ono
Journal:  Pharmacogenomics       Date:  2020-06-03       Impact factor: 2.533

3.  Genomic diversity and post-admixture adaptation in the Uyghurs.

Authors:  Yuwen Pan; Chao Zhang; Yan Lu; Zhilin Ning; Dongsheng Lu; Yang Gao; Xiaohan Zhao; Yajun Yang; Yaqun Guan; Dolikun Mamatyusupu; Shuhua Xu
Journal:  Natl Sci Rev       Date:  2021-09-11       Impact factor: 17.275

4.  Stable expression of human cytochrome P450 2D6*10 in HepG2 cells.

Authors:  Jian Zhuge; Ying-Nian Yu; Xiao-Dan Wu
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

5.  A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo.

Authors:  Nael Al Koudsi; Jasjit S Ahluwalia; Shih-Ku Lin; Edward M Sellers; Rachel F Tyndale
Journal:  Pharmacogenomics J       Date:  2009-04-14       Impact factor: 3.550

Review 6.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

7.  Association of single nucleotide polymorphisms of cytochrome P450 enzymes with experience of vasomotor, vaginal and musculoskeletal symptoms among breast cancer patients: a systematic review.

Authors:  Carmen W H Chan; Bernard M H Law; Marques S N Ng; Corinna C Y Wong; Carissa W Y Wong; Morgan Quinley; Jessica M Orgusyan; Ka Ming Chow; Mary M Y Waye
Journal:  BMC Cancer       Date:  2021-05-18       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.